By Ciara Duffy, member of the RPS English Pharmacy Board
As a vital life science, pharmacy facilitates the delivery of medical science, bridging the gap between groundbreaking innovations and their implementation to benefit patients. For pharmacy professionals, the urgency to embrace and lead in this era of change has never been greater.
I recently attended the Kadan’s Innovation Summit, which brought together pioneers from academia, healthcare, and industry to reimagine the future of life sciences. The event spotlighted transformative breakthroughs in Artificial Intelligence (AI), genomics, and advanced manufacturing while underscoring the critical role of collaboration in driving progress. These innovations, aligned with the UK Government’s Life Sciences Vision, are reshaping patient care and positioning the UK as a global leader in healthcare innovation.
Insights on Genomics, AI, and inflammation
Prof. Peter van der Spek, Head of Bioinformatics at Erasmus MC, shared insights into genomics and AI’s impact on understanding immune cell dynamics and inflammation.
AI-powered technologies, such as advanced diagnostic imaging, are revolutionising disease detection by identifying key biomarkers for cancers and inflammation-related disorders. These tools are not just accelerating diagnosis but are also enabling the development of precision medicines tailored to individual patients.
As chronic conditions increasingly burden healthcare systems, leveraging AI and genomics to create preventative and personalised strategies will be pivotal for the future of pharmaceutical care. Pharmacy professionals across all sectors will be essential in delivering these advanced medicines to patients.
Revolutionising manufacturing and quality assurance
A key discussion on manufacturing innovation highlighted the transformative impact of technology on pharmaceutical supply chains. Jitesh Halai, CEO of OneSc, demonstrated how digital platforms are revolutionising processes through automation, enhanced transparency, and real-time batch monitoring.
AI tools are also being explored to help address medicine shortages by predicting supply chain disruptions.
Another notable innovation discussed was the focus on GMP manufacture of phages to counteract antimicrobial resistance.
New legislation, particularly the Human Medicines (Amendment: Modular Manufacture and Point of Care) Regulations 2024, positions the UK as a global leader in innovative and patient-centred pharmaceutical manufacturing. For Qualified Persons (QPs) and quality professionals, these changes present both challenges and opportunities. Moving away from traditional centralised manufacturing and QC models introduces complexities in ensuring compliance, managing new workflows, and maintaining product integrity. However, it also offers significant advantages, such as improved flexibility, enhanced innovation potential, and streamlined processes that can benefit organisations across the life sciences sector.
By integrating AI-enabled workflows and fostering strategic partnerships, the life sciences sector can build resilient, high-quality supply chains capable of producing complex therapies, such as ATMPs, more efficiently and effectively.
Collaborating with NHS pharmacy on governance and technical service delivery, alongside industry partners, will be essential for translating this ambitious vision into success.
Harnessing the power of collaboration
Collaboration was the prevailing theme of the day, with case studies such as the Paris-Atelier Cancer Cluster and the University of Glasgow’s Living Laboratory demonstrating how partnerships bridge the gap between innovation and clinical application. Programmes like the Living Laboratory, where new treatments are tested in real-world NHS settings, ensure that innovations are both effective and practical.
For pharmacy professionals, this highlights the critical importance of cross-disciplinary efforts to implement innovative medicines safely and efficiently, whether for clinical trials or commercial products. Public-private partnerships enable faster and more effective translation of research into practice, ensuring that patients reap the benefits of healthcare advancements.
Pharmacists have a unique role
The event underscored that the future of life sciences hinges on innovation, collaboration, and visionary leadership. Breakthroughs in genomics, AI, and advanced manufacturing are reshaping patient care and creating opportunities to drive economic growth.
This is a pivotal time for life sciences professionals to join forces and drive these advancements forward. Pharmacists, as medicines experts have a unique and vital role to play. Our expertise is critical in ensuring innovative medicines and innovations in manufacturing are effectively integrated into healthcare systems to benefit patients.
Government funding, policy makers, and cross-sector collaboration will be essential to build the infrastructure and support needed to unlock these opportunities. By working together, promoting shared learning and embracing innovation, life sciences professionals can position the UK as a global leader in healthcare innovation and deliver transformative outcomes for patients worldwide, with pharmacy as a key stakeholder in the life sciences sector.
Now is the time to act—together, we can transform the landscape of life sciences and deliver on the promise of better health for all.
Find out more about RPS Science and Research.
Read more RPS blogs.